Chinese clinical oncology最新文献

{"title":"Clinical evidence on a Coriolus versicolor-based vaginal gel for HPV-related cervical disease: a narrative review.","authors":"Emmanuel Sánchez Díaz, Gabriel Levin, Andreina Fernandes, Angelica Fletcher, René Pareja","doi":"10.21037/cco-25-100","DOIUrl":"10.21037/cco-25-100","url":null,"abstract":"<p><strong>Background and objective: </strong>Human papillomavirus (HPV) infection is the most common sexually transmitted disease worldwide. Its persistence may lead to cervical dysplasia and, eventually, cervical cancer. Currently, there are no approved treatments specifically targeting HPV infection or low-grade squamous intraepithelial lesions (LSILs). A multicomponent vaginal gel containing Trametes versicolor extract, prebiotics, moisturizing agents, and anti-inflammatory coadjuvants has been developed to support natural HPV clearance and promote lesion healing or regression. The aim of this review is to summarize the available evidence regarding a multi-ingredient vaginal gel for HPV infection and cervical low-grade dysplasia treatment and to provide a critical review of the literature.</p><p><strong>Methods: </strong>A structured literature search was performed in MEDLINE, Embase, and Scopus without language or date restrictions. Additional records were identified through ClinicalTrials.gov and Google Scholar. Both peer-reviewed publications and conference abstracts reporting clinical outcomes of Trametes versicolor-based vaginal gel (Papilocare® or Palomacare®) were included.</p><p><strong>Key content and findings: </strong>Papilocare®/Palomacare® is available in over 65 countries across Europe, Africa, Asia, and Latin America. The clinical evidence includes two pilot studies, two prospective non-controlled interventional studies, one randomized clinical trial, and one retrospective observational study. This narrative review summarizes their design, results, strengths, and limitations. Ethical issues related to trial design, lack of biopsy confirmation, absence of blinding, and retrospective registration are discussed. Although some preliminary data suggest potential benefits in epithelial repair and HPV clearance, current evidence remains insufficient to support its routine clinical use.</p><p><strong>Conclusions: </strong>Further independent, well-designed, and adequately powered randomized trials are required to confirm the safety and efficacy of this formulation. Strengthening methodological rigor will be essential to define its role in HPV-related cervical disease management.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 1","pages":"9"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147376229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endocrine therapy in estrogen receptor-low breast cancer: new evidence, persistent questions.","authors":"Tomás Reinert, Maiane Maria Pauletto, Flavio Vinicius Costa Ferreira, Martina Parenza Arenhardt","doi":"10.21037/cco-2025-aw-125","DOIUrl":"https://doi.org/10.21037/cco-2025-aw-125","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 1","pages":"18"},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147375869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAR T cells in chronic lymphocytic leukemia: a long unusual journey?","authors":"Khalil Saleh, Hampig Raphael Kourie, Fadi G Haddad","doi":"10.21037/cco-2025-1-179","DOIUrl":"https://doi.org/10.21037/cco-2025-1-179","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 1","pages":"14"},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147376234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peri-operative radiotherapy for pancreatic ductal adenocarcinoma: current evidence and future directions: a narrative review.","authors":"Ayah Erjan, Krishan R Jethwa","doi":"10.21037/cco-25-98","DOIUrl":"10.21037/cco-25-98","url":null,"abstract":"<p><strong>Background and objective: </strong>Pancreatic ductal adenocarcinoma (PDAC) carries a high risk of locoregional and distant recurrence, even after curative-intent surgery. The adoption of increasingly effective multi-agent chemotherapy, most notably modified FOLFIRINOX (mFOLFIRINOX), has shifted the focus toward understanding the incremental value of perioperative radiotherapy (RT), which remains controversial. This review aimed to summarize current evidence on the role of RT in both the adjuvant and neoadjuvant settings for resectable and borderline resectable PDAC.</p><p><strong>Methods: </strong>This narrative, non-systematic review synthesized randomised trials, retrospective analyses, and contemporary guidelines on peri-operative RT in PDAC. Literature from 2000-2025 was identified using PubMed and Google Scholar. Additional references were identified through manual review of bibliographies from key articles.</p><p><strong>Key content and findings: </strong>The review discusses historical controversies around perioperative RT, recent evidence supporting benefit of post-operative chemoradiotherapy (CRT) in select patients, and the evolving use of RT in neoadjuvant strategies. Trials such as PREOPANC, ESPAC-5, and PRODIGE-44 are highlighted. Modern contouring atlases and planning techniques are also reviewed, emphasizing the rationale for elective coverage based on failure patterns.</p><p><strong>Conclusions: </strong>Perioperative RT may benefit selected PDAC patients when applied within a risk-adapted framework that accounts for underlying systemic-risk biology. Ongoing work is needed to determine which clinical or biologic markers reliably identify patients most likely to benefit from RT in the setting of intensified systemic therapy.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 1","pages":"7"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147376130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microsurgery of a rare case of abducens schwannoma: surgical techniques.","authors":"Jingqi Hu, Hailiang Tang, Ming Xu, Jian Xu, Ping Zhong","doi":"10.21037/cco-2025-aw-126","DOIUrl":"10.21037/cco-2025-aw-126","url":null,"abstract":"<p><p>Abducens schwannoma is relatively very rare, and accounts for only about 1% of all intracranial schwannomas. Here, we report microsurgical resection of a rare case of cisternal-segment abducens schwannoma in a female patient. Upon physical examination, the patient showed no eye movement symptoms, and facial & auditory nerves function were normal, but showed slight unsteady walking and positive Romberg sign. Magnetic resonance imaging (MRI) scan of the brain revealed a mass located at the right cerebellopontine angle (CPA), and the tumor was partially enhanced after contrast MRI scan. Thus, schwannoma is suspected before surgery, but it's difficult to identify its origin by MRI images. Considering tumor compression to brain stem and available microsurgical techniques nowadays, we selected craniotomy surgery for the patient, and classic retro-sigmoid approach was recommended, which is a safe and commonly used surgical approach. During the surgery, the tumor was found to arise from the abducens nerve, and a total resection of the schwannoma was finally achieved under intra-operative neuro-monitoring. The patient tolerated the surgery very well, but had transient abducens paralysis and ataxia after surgery, and gradually improved in 3 months. The follow-up brain MRI images 3 months after surgery indicated no residual or relapse of the tumor.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 1","pages":"5"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147376135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bispecific immune-angiogenic blockade in extensive-stage small-cell lung cancer-positioning ivonescimab.","authors":"Èlia Sais Girona, Joaquim Bosch-Barrera","doi":"10.21037/cco-2025-aw-127","DOIUrl":"https://doi.org/10.21037/cco-2025-aw-127","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 1","pages":"20"},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147376194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of metastatic pancreatic cancer with concurrent BRAF V600E mutation and germline BRCA2 mutation: a case report.","authors":"Xiaoting Ma, Mei Guan, Ningning Li, Ying Liu, Huanwen Wu, Yuejuan Cheng, Yi Ba","doi":"10.21037/cco-2025-aw-132","DOIUrl":"10.21037/cco-2025-aw-132","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic ductal adenocarcinoma (PDAC) with concurrent somatic BRAF V600E and germline BRCA2 mutations is exceedingly rare. While BRAF mutations define a distinct KRAS-wildtype subset, and BRCA2 mutations are associated with homologous recombination deficiency and sensitivity to platinum-based therapy/PARP inhibitors, the clinical behavior and optimal treatment strategy for tumors harboring both alterations remain unknown. This case report adds to the limited literature by detailing the therapeutic course and inherent challenges in managing this unique molecular subtype.</p><p><strong>Case description: </strong>A 61-year-old male underwent distal pancreatectomy for moderately differentiated PDAC (pT2N1M0). Molecular profiling revealed a somatic BRAF V600E mutation and a germline BRCA2 pathogenic mutation (p.F1241Vfs*17) with somatic second-hit inactivation (p.E2953*), indicating biallelic loss. Post-operative adjuvant gemcitabine/nab-paclitaxel was administered. Upon recurrence, platinum-based therapy (S-1/oxaliplatin) was poorly tolerated and ineffective. Subsequent olaparib maintenance achieved a transient partial response (PR) [progression-free survival (PFS): 5.5 months] before progression. Therapy was then switched to dabrafenib/trametinib (BRAF/MEK inhibition), which led to initial tumor shrinkage but was followed by rapid disease progression with malignant ascites. The patient died 22 months post-surgery despite combined targeted therapy and intraperitoneal chemotherapy.</p><p><strong>Conclusions: </strong>This case highlights that the co-occurrence of BRAF V600E and biallelic BRCA2 mutations may confer a unique clinical phenotype with suboptimal or transient responses to both BRCA-directed therapies (platinum, olaparib) and BRAF/MEK inhibition. It underscores the complexity of precision oncology in PDAC, where genotype does not always predict therapeutic response, potentially due to factors like tumor heterogeneity, stromal barriers, or undiscovered resistance mechanisms. Future large-scale studies are needed to define prognostic implications and explore potential combination strategies (e.g., BRAF/MEK + PARP inhibitors) for this rare molecular cohort.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 1","pages":"13"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147376147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing the frontiers of hepatocellular carcinoma treatment: a comprehensive review of past, ongoing, and future clinical trials.","authors":"Sam Y Son, Ruben Geevarghese, Niloufar Valizadeh, Hooman Yarmohammadi","doi":"10.21037/cco-25-53","DOIUrl":"10.21037/cco-25-53","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related deaths worldwide. The therapeutic landscape continues to evolve rapidly, with growing evidence supporting a range of treatment options across all disease stages. Notably, advancements in systemic therapies in advanced HCC have shifted first-line treatment preferences toward immune checkpoint inhibitor-based regimens, often combined with anti-angiogenic agents. These regimens have demonstrated meaningful improvements in overall survival, progression-free survival, and quality of life compared with historical standards such as sorafenib. At the same time, locoregional therapies (LRTs), including transarterial chemoembolization (TACE), transarterial radioembolization (TARE), ablation techniques, and external beam radiation, continue to play a central role in the management of intermediate and selected early or advanced-stage disease. Increasing understanding of tumor biology and treatment-related immunomodulation has prompted renewed interest in the synergistic potential of combining LRTs with systemic immunotherapy. Early-phase and ongoing later-phase trials suggest that these combined approaches may enhance antitumor immune activation, improve local tumor control, and potentially extend survival in carefully selected patients. This review summarizes the clinical trial evidence to date, emphasizing locoregional image-guided interventional therapies, systemic treatments, and emerging combination strategies. It highlights key findings from past and current clinical trials, discussing evolving treatment paradigms, and outlines future directions that may shape the next generation of multimodal therapy for patients with HCC.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 1","pages":"11"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147376223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-reported outcomes in TALAPRO-2 trial: addressing data integrity and comparative clinical benefit in mCRPC.","authors":"Nobuaki Matsubara","doi":"10.21037/cco-2026-1-0007","DOIUrl":"https://doi.org/10.21037/cco-2026-1-0007","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 1","pages":"21"},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147376105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The phase III MECCA study on metronomic chemo-endocrine therapy in advanced breast cancer-the results that so many have been waiting for.","authors":"Piotr J Wysocki","doi":"10.21037/cco-2025-aw-129","DOIUrl":"https://doi.org/10.21037/cco-2025-aw-129","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 1","pages":"16"},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147376151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}